

<https://doi.org/10.1038/s41467-018-07917-0>

OPEN

Author Correction: Reprogramming triggers endogenous L1 and *Alu* retrotransposition in human induced pluripotent stem cells

Sabine Klawitter^{1,10}, Nina V. Fuchs^{1,2}, Kyle R. Upton³, Martin Muñoz-Lopez⁴, Ruchi Shukla⁵, Jichang Wang², Marta Garcia-Cañadas⁴, Cesar Lopez-Ruiz⁴, Daniel J. Gerhardt³, Attila Sebe¹, Ivana Grabundzija², Sylvia Merkert⁶, Patricia Gerdes³, J. Andres Pulgarin⁴, Anja Bock¹, Ulrike Held¹, Anett Witthuhn⁶, Alexandra Haase⁶, Balázs Sarkadi⁷, Johannes Löwer¹, Ernst J. Wolvetang⁸, Ulrich Martin⁶, Zoltán Ivics¹, Zsuzsanna Izsvák², Jose L. Garcia-Perez⁴, Geoffrey J. Faulkner^{3,9} & Gerald G. Schumann¹

Correction to: *Nature Communications*; <https://doi.org/10.1038/ncomms10286>; published online 8 January 2016

This Article contains an error in the author affiliations. The correct affiliation for author Ruchi Shukla is ‘MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, Edinburgh, EH4 2XU, UK’, and is not ‘Mater Research Institute – University of Queensland, TRI Building, Woolloongabba QLD 4102, Australia’.

Published online: 19 December 2018



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018

¹Division of Medical Biotechnology, Paul-Ehrlich-Institute, D-63225 Langen, Germany. ²Max-Delbrück-Center for Molecular Medicine, D-13125 Berlin, Germany. ³Mater Research Institute, University of Queensland, TRI Building, Woolloongabba, Brisbane, Queensland 4102, Australia. ⁴Department of Human DNA Variability, Pfizer/University of Granada and Andalusian Regional Government Center for Genomics and Oncology (GENYO), PTS Granada, 18016 Granada, Spain. ⁵MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK. ⁶Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiac, Thoracic, Transplantation, and Vascular Surgery; REBIRTH, Cluster of Excellence, Hannover Medical School, D-30625 Hannover, Germany. ⁷Department of Biophysics and Radiation Biology, Semmelweis University, H-1094 Budapest, Hungary. ⁸Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia. ⁹Queensland Brain Institute, University of Queensland, Brisbane, Queensland 4072, Australia. ¹⁰Present address: Division of Inborn Metabolic Diseases, University Children's Hospital, D-69120 Heidelberg, Germany. These authors contributed equally: Sabine Klawitter, Nina V. Fuchs, Kyle R. Upton, Martin Muñoz-Lopez. The original article can be found online at <https://doi.org/10.1038/ncomms10286>. Correspondence and requests for materials should be addressed to J.L.G.-P. (email: jlgp@genyo.es) or to G.J.F. (email: faulknergj@gmail.com) or to G.G.S. (email: Gerald.Schumann@pei.de)